NCT01460602 - Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | Biotech Hunter

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma

Interventions

DRUG

MTD of Velcade, Nipent and Rituxan established in Part 1

"One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"

Trial Locations (1)

71103

LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center, Shreveport